COMP <GO>
OBX vs ALMS // GROSS PROFIT MARGIN
Obsidian Therapeutics Inc. (NASDAQ) VS. Alumis Inc. (NASDAQ) • 15-METRIC TALLY: OBX 3
— ALMS 0
■ METRIC PARITY
LAST: $14.52 (-0.48%) • MKT CAP: $896.9M
gross-margins
—
LAST: $6.89 (-3.37%) • MKT CAP: $891.8M
gross-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OBX VS. ALMS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | OBX | ALMS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -10.09% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 0.20 | +25.80 | OBX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.3 | 39.9 | +13.40 | OBX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $896.9M | $891.8M | $5.1M | OBX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | OBX REV | ALMS REV | OBX GROSS % | ALMS GROSS % | OBX FCF | ALMS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $24.1M | — | — | -$90.5M | -$370.2M |
| FY 2024 | $0 | $0 | — | — | -$75.8M | -$256.8M |
| FY 2023 | — | $0 | — | — | — | -$130.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OBX // BETA —
ALMS // BETA —